Development and validation of a liquid chromatography–mass spectrometry method for simultaneous determination of metoprolol and telmisartan in rat plasma and its application to pharmacokinetic study

Nandi, Utpal; Dan, Shubhasis; Pal, Tapan Kumar

doi:10.1007/s40005-015-0180-5

Cited by 12 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results from the matrix effect and extraction recovery studies of ECN and LST are listed in Table 2. The proteins from the plasma samples were removed using a solvent precipitation method, which is relatively straightforward and rapid compared to the other methods [26]. Although this pretreatment method retains solvent-soluble compounds, such as lipids and fatty acids, in the analytical sample [27], negligible matrix effects were observed on the ECN analysis (ranging from 83.3 ± 7.7% to 93.1 ± 0.9%) in this study.…”

Section: Matrix Effect and Extraction Recoverymentioning

confidence: 94%

Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry Method for Pharmacokinetic Evaluation of 7β-(3-Ethyl-cis-crotonoyloxy)-1α-(2-methylbutyryloxy)-3,14-dehydro-Z-notonipetranon in Rats

et al. 2020

View full text Add to dashboard Cite

Recently, potent neuroprotective and anti-diabetic effects of 7β-(3-Ethyl-cis-crotonoyloxy)-1α-(2-methylbutyryloxy)-3,14-dehydro-Z-notonipetranone (ECN), a sesquiterpenoid isolated from Tussilago farfara Linnaeus, have been elucidated. To facilitate further pre-clinical evaluation in rats, an analytical method for the determination of ECN in rat plasma was developed and optimized by using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Plasma samples were pretreated by the protein precipitation method with an acetonitrile solution of losartan (LST) as the internal standard. Chromatographic separation was performed using a an Octadecyl-silica (ODS) column (2.6 µm, 100 x 4.6 mm) in the isocratic mode. The mobile phase, comprising 10 mM ammonium formate in water pH 5.75) and acetonitrile (11:89, v/v), was eluted at a flow rate of 0.4 mL/min. Mass spectrometric detection was performed in the multiple reaction monitoring mode with positive electrospray ionization, and the mass transitions of ECN and LST were m/z 431.3 to 97.3 and m/z 423.1 to 207.2, respectively. The calibration curves of spiked plasma samples were linear in the 10.0–10,000 ng/mL range (r2 > 0.996). The lower limit of quantification (LLOQ) was determined as 10.0 ng/mL. Validation was conducted in the LLOQ, and three quality control (QC) sample levels (10.0, 25.0, 3750, and 7500 ng/mL) were studied. Among them, the relative standard deviation for the within- and between-run precisions was under 9.90%, and the relative error of the accuracies was within the −8.13% to 0.42% range. The validated method was successfully employed to investigate the pharmacokinetic properties of ECN in rats, which revealed the linear pharmacokinetic behavior of ECN for the first time.

show abstract

Section: Matrix Effect and Extraction Recoverymentioning

confidence: 94%

Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry Method for Pharmacokinetic Evaluation of 7β-(3-Ethyl-cis-crotonoyloxy)-1α-(2-methylbutyryloxy)-3,14-dehydro-Z-notonipetranon in Rats

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Mean value should be within 15% of the nominal value except at LLOQ, where it should not deviate by more than 20%. The precision determined at each concentration level should not exceed 15% of the CV except for the LLOQ, where it should not exceed 20% of the CV [ 26–27 , 29–32 ]. The ‘within-run’ precision and accuracy (assessment of precision and accuracy during a single analytical run) was estimated by analyzing five replicates of EPL and EPLT at three different QC levels-low, middle and high (LQC, MQC and HQC) in human plasma.…”

Section: Methodsmentioning

confidence: 99%

“…The LLOQ was defined as the lowest concentration yielding a S/N of at least 5 with a CV < 20% and accuracy of 80–120%. The acceptance criterion for other standard concentrations was within 15% deviation from the nominal values [ 26–27 , 29–32 ].…”

Section: Methodsmentioning

confidence: 99%

LC–MS/MS Assay for Quantitation of Enalapril and Enalaprilat in Plasma for Bioequivalence Study in Indian Subjects

Halder

Dan

Pal³

et al. 2017

Future Sci. OA

Self Cite

View full text Add to dashboard Cite

Background:Enalapril (EPL) is an angiotensin-converting enzyme inhibitor for the treatment of hypertension and chronic heart failure. Enalaprilat (EPLT) is an active metabolite that contributes to the overall activity of EPL.Aim:To quantitate EPL along with its metabolite EPLT using LC–MS/MS, a bioanalytical method was developed and validated with tolbutamide in human plasma using a protein precipitation technique.Results:The sensitive and selective method has an LLOQ of 1 ng/ml with a linearity range of 1–500 ng/ml for both EPL and EPLT using 300 µl of plasma without any matrix effect.Conclusion:Linearity, specificity, accuracy, precision and stability, as well as its application to the analysis of plasma samples after oral administration of 20 mg of EPL maleate in healthy volunteers demonstrate applicability to bioavailability/bioequivalence studies.

show abstract

“…To explore the pharmacokinetics of crocetin, several in vivo studies were executed using animal models. , Animal experiments were conducted as per the “Committee for Control and Supervision of Experiments on Animals (CCSEA)” (Government of India, New Delhi, India) guidelines with prior approval of study protocol from our “Institutional Animal Ethics Committee” (Approval number: IAEC/79/255/8/2021 and IAEC/80/278/2/2022). Detailed methodology for each study is described in the Supporting Information.…”

Section: Experimental Sectionmentioning

confidence: 99%

ADME/PK Insights of Crocetin: A Molecule Having an Unusual Chemical Structure with Druglike Features

Manhas,

Dhiman,

Kour

et al. 2024

ACS Omega

Self Cite

View full text Add to dashboard Cite

Crocetin is a promising phyto-based molecule to treat Alzheimer's disease (AD). The chemical structure of crocetin is incongruent with various standard structural features of CNS drugs. As poor pharmacokinetic behavior is the major hurdle for any candidate to become a drug, we elucidated its druggable characteristics by implementing in silico, in vitro, and in vivo approaches, as limited ADME/PK information is available. Results demonstrate several attributes of crocetin based on rules of drug-likeness, lipophilicity, pK a , P-gp inhibitory activity, plasma stability, RBC partitioning, metabolic stability, CYP inhibitory action, blood-brain barrier (BBB) permeability, oral bioavailability, and pharmacokinetic interaction with marketed anti-Alzheimer's drugs (memantine, donepezil, galantamine, and rivastigmine). However, aqueous solubility, chemical stability, plasma protein binding, and P-gp induction are some concerns associated with this molecule that should be taken into consideration during its further development. Overall results indicate favorable ADME/PK behavior and potential druggable candidature of crocetin.

show abstract

Development and validation of a liquid chromatography–mass spectrometry method for simultaneous determination of metoprolol and telmisartan in rat plasma and its application to pharmacokinetic study

Cited by 12 publications

References 23 publications

Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry Method for Pharmacokinetic Evaluation of 7β-(3-Ethyl-cis-crotonoyloxy)-1α-(2-methylbutyryloxy)-3,14-dehydro-Z-notonipetranon in Rats

Development and Validation of Liquid Chromatography-Tandem Mass Spectrometry Method for Pharmacokinetic Evaluation of 7β-(3-Ethyl-cis-crotonoyloxy)-1α-(2-methylbutyryloxy)-3,14-dehydro-Z-notonipetranon in Rats

LC–MS/MS Assay for Quantitation of Enalapril and Enalaprilat in Plasma for Bioequivalence Study in Indian Subjects

ADME/PK Insights of Crocetin: A Molecule Having an Unusual Chemical Structure with Druglike Features

Contact Info

Product

Resources

About